Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72695 | 0.88 | ALDH1A1 (0.42) | KMT2AHRH3 | |
| SCHEMBL72224 | 0.88 | ALDH1A1 (0.42) | KMT2AHRH3 | |
| SCHEMBL74746 | 0.74 | ALDH1A1 (0.42) | KMT2ASMN1; SMN2HPGD | |
| SCHEMBL73082 | 0.73 | ALDH1A1 (0.41) | KMT2A | |
| SCHEMBL9935314 | 0.72 | HSD17B10 (0.36) | HSD17B10KMT2ASMN1; SMN2HPGDBTK | |
| SCHEMBL2434336 | 0.71 | HSD17B10 (0.38) | HSD17B10KMT2ASMN1; SMN2HPGDBTK | |
| SCHEMBL2465398 | 0.70 | HSD17B10 (0.40) | HSD17B10KMT2ASMN1; SMN2HPGDBTK | |
| SCHEMBL25474802 | 0.67 | LMNA (0.39) | HSD17B10KMT2ASMN1; SMN2BTK | |
| SCHEMBL9680450 | 0.67 | LMNA (0.39) | HSD17B10KMT2ASMN1; SMN2BTK | |
| SCHEMBL25490288 | 0.67 | LMNA (0.39) | HSD17B10KMT2ASMN1; SMN2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | HSD17B10 651/4885KMT2A 568/4885SMN1; SMN2 4739/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | HSD17B10 861/4885KMT2A 656/4885SMN1; SMN2 4702/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | HSD17B10 736/4885KMT2A 881/4885SMN1; SMN2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.